Endpoints 11: Azalea Therapeutics melds gene editing and CAR-T

Endpoints 11 2026: Doudna-co-founded Azalea Therapeutics aims to enter the clinic next year with a CRISPR-based in vivo CAR-T therapy for blood cancers. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…

Source: Endpoints News